NASDAQ:CLSD - Clearside Biomedical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.46 +0.04 (+2.82 %) (As of 03/21/2019 04:10 AM ET)Previous Close$1.42Today's Range$1.41 - $1.4952-Week Range$0.99 - $15.33Volume648,764 shsAverage Volume1.13 million shsMarket Capitalization$52.62 millionP/E Ratio-0.54Dividend YieldN/ABeta-1.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia. Receive CLSD News and Ratings via Email Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSD Previous Symbol CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone678-270-3631Debt Debt-to-Equity Ratio0.40 Current Ratio4.10 Quick Ratio4.59Price-To-Earnings Trailing P/E Ratio-0.54 Forward P/E Ratio-1.04 P/E GrowthN/A Sales & Book Value Annual Sales$30,000.00 Price / Sales1,753.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book1.74Profitability EPS (Most Recent Fiscal Year)($2.69) Net Income$-82,820,000.00 Net MarginsN/A Return on Equity-150.37% Return on Assets-108.27%Miscellaneous EmployeesN/A Outstanding Shares36,039,000Market Cap$52.62 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions What is Clearside Biomedical's stock symbol? Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD." How were Clearside Biomedical's earnings last quarter? Clearside Biomedical Inc (NASDAQ:CLSD) issued its earnings results on Tuesday, March, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.13. The company earned $0.03 million during the quarter. View Clearside Biomedical's Earnings History. When is Clearside Biomedical's next earnings date? Clearside Biomedical is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Clearside Biomedical. What price target have analysts set for CLSD? 8 equities research analysts have issued twelve-month target prices for Clearside Biomedical's stock. Their forecasts range from $4.00 to $29.00. On average, they anticipate Clearside Biomedical's share price to reach $11.8333 in the next twelve months. This suggests a possible upside of 710.5% from the stock's current price. View Analyst Price Targets for Clearside Biomedical. What is the consensus analysts' recommendation for Clearside Biomedical? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical. Has Clearside Biomedical been receiving favorable news coverage? News headlines about CLSD stock have trended very negative recently, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clearside Biomedical earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. Are investors shorting Clearside Biomedical? Clearside Biomedical saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,076,453 shares, an increase of 49.0% from the February 15th total of 1,393,319 shares. Based on an average daily volume of 2,696,116 shares, the days-to-cover ratio is currently 0.8 days. Currently, 8.5% of the company's shares are short sold. View Clearside Biomedical's Current Options Chain. Who are some of Clearside Biomedical's key competitors? Some companies that are related to Clearside Biomedical include Paratek Pharmaceuticals (PRTK), Poxel (PXXLF), Recro Pharma (REPH), Molecular Templates (MTEM), Aratana Therapeutics (PETX), Nature's Sunshine Products (NATR), VBI Vaccines (VBIV), Synlogic (SYBX), BELLUS Health (BLUSF), REDHILL BIOPHAR/S (RDHL), Menlo Therapeutics (MNLO), TAIWAN LIPOSOME/S (TLC), Cue Biopharma (CUE), Millendo Therapeutics (MLND) and ProMetic Life Sciences (PFSCF). What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Ocular Therapeutix (OCUL), General Electric (GE), Mattel (MAT), Ultra Clean (UCTT), Sarepta Therapeutics (SRPT), Immunomedics (IMMU), Syndax Pharmaceuticals (SNDX), TG Therapeutics (TGTX), Twitter (TWTR) and Paratek Pharmaceuticals (PRTK). Who are Clearside Biomedical's key executives? Clearside Biomedical's management team includes the folowing people: Mr. Daniel H. White, Founder, Pres, CEO & Director (Age 52)Mr. Charles A. Deignan, CFO & Sec. (Age 55)Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)Mr. Leslie B. Zacks, Gen. Counsel & Chief Compliance Officer (Age 50)Mr. Rick McElheny, VP of Corp. Devel. When did Clearside Biomedical IPO? (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (3.70%), Northpointe Capital LLC (1.76%), Millennium Management LLC (1.71%), Geode Capital Management LLC (0.95%), Geode Capital Management LLC (0.95%) and Two Sigma Investments LP (0.65%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical. Which institutional investors are selling Clearside Biomedical stock? CLSD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Northpointe Capital LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Clearside Biomedical. Which institutional investors are buying Clearside Biomedical stock? CLSD stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Tekla Capital Management LLC, Virtu Financial LLC, SG Americas Securities LLC, Sphera Funds Management LTD., Bank of New York Mellon Corp and Alambic Investment Management L.P.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical. How do I buy shares of Clearside Biomedical? Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Clearside Biomedical's stock price today? One share of CLSD stock can currently be purchased for approximately $1.46. How big of a company is Clearside Biomedical? Clearside Biomedical has a market capitalization of $52.62 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. What is Clearside Biomedical's official website? The official website for Clearside Biomedical is http://www.clearsidebio.com. How can I contact Clearside Biomedical? Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected] MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 236 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 421MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?